和黄医药宣布完成Saffron全球III期临床试验的入组,研究Orpathys®和Tagrisso®组合用于某些EGFR突变肺癌患者

美股速递
Nov 05, 2025

和黄医药宣布完成Saffron全球III期临床试验的入组,该试验研究Orpathys®与Tagrisso®的联合应用,针对在使用Tagrisso®后出现MET基因过表达和/或扩增的某些肺癌患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10